ARNS issues joint statement on new packaging on Relvar

ARNS issues joint statement on new packaging on Relvar

On behalf of the Association of Respiratory Nurse Specialists, Asthma UK, British Lung Foundation, British Thoracic Society, Education for Health, Primary Care Respiratory Society, Respiratory Education UK, the Royal Pharmaceutical Society, and the UK Clinical Pharmacy Association

Relvar® (flucticasone furoate / vilanterol) Ellipta Packaging Change

The above partner organisations welcome the changes announced by GSK in colour and labelling of Relvar®  Ellipta® inhaler across Europe, in response to concerns expressed by the respiratory community. Concerns about the potential for serious patient safety risks associated with the name and colour of Relvar® (flucticasome furoate / vilaterol) Ellipta® were first raised in February 2014, and were shared between partner organisations. The main concerns were surrounding the use of colour blue for the mouthpiece of the lower strength inhaler, since the product is not designed for relieving symptoms.   Read the full statement: Relvar Statement final 3 December 2014

Thanks to all our Partner organisations

AstraZeneca Boehringer Chiesi NAPP gsk